Parkinson's Disease: A Neurodegenerative Disease (original) (raw)

Abstract

Parkinson’s disease is characterized by tremor, stiffness, rigid muscles, bradykinesia, slowness of movement, instability leading to falls, memory and talking difficulties, fatigue, writing modifications (micrography) and dementia. In addition, depression, urinary (bladder) problems, constipation, decreased ability to smell and sleep disruption are among the symptoms associated to the PD. As Parkinson’s cannot be eradicate, treatments are oriented toward a slow decline and deterioration and therefore, only palliative care predominates. Mutations of 6 genes (SNCA, LRRK2, PRKN, DJ1, PINK1 and ATP13A2), are the cause of familial Parkinsonism. They are playing a role in the metabolism of α-synucleine, in mitochondrial control, oxidative stress, lysosomal functions, transport and recycling of proteins and immunologic activities. Five stages with increased gravity have been identified. From stage 1 to 3, symptoms may be treated with pharmacological drugs. At stages 4 and 5, the patient needs assistive help and an ambulatory walker device. L-dopa is transformed in dopamine in the brain. Treatments for speech disorders increase the disability of these symptoms. Dopamine agonists, MAO-B and COMT inhibitors contribute to help break down dopamine, an anticholinergic drug aiming to reduce tremors and muscle rigidity. Death is occurring within 7 to 15 years.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (13)

  1. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord. 2003;18:1931.
  2. Mandemakers W, Morais VA, De Stooper B. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J Cell Science. 2007;120:1707-18.
  3. Bekris LM, Mata IF, Zabetian. The genetics of Parkinson Disease. J of Geriatric Psychiatry and Neurology. 2010;23(4):228-42.
  4. Vekrellis, K, Xilouri M, Emmanouilidou E, Rideout H J, Stefanis L. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 2011;10:1015-25.
  5. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol. 2013;70:859-66.
  6. Connolly B S, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311:1670- 83.
  7. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386:896-912.
  8. Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson's disease. J Parkinsons Dis. 2015;5:681-97.
  9. Brundin P, Atkin G, Lamberts JT. Basic science breaks through: new therapeutic advances in Parkinson's disease. Mov Disord. 2015;30:1521-7.
  10. Citation: Goldberg M. Parkinson's Disease: A Neurodegenerative Disease. Jour Clin Med Res. 2022;3(2):1-6. DOI: http://dx.doi.org/10.46889/JCMR.2022.3203
  11. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 2016;15:1257-72.
  12. Poewe W, Seppi K, Tanner C, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.
  13. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 4. 2009:e5515.